FDA approves Baxter's TISSEEL for general hemostasis in surgery

Baxter International Inc. (NYSE:BAX) announced today that the U.S. Food and Drug Administration (FDA) has approved TISSEEL [Fibrin Sealant] to include general hemostasis in surgery when control of bleeding by standard surgical techniques is ineffective or impractical. TISSEEL is effective in heparinized patients. TISSEEL mimics the final stages of the body's own blood clotting cascade, creating a clot that adheres to the wound surface and helps achieve hemostasis.

"The expanded indication for TISSEEL offers more surgeons an effective tool for controlling bleeding across a wider variety of surgical procedures," said Sibu Saha, M.D., Professor of Surgery, University of Kentucky. "This includes patients who have been treated with heparin who may have unique treatment challenges, which was the case for some of the patients involved in Baxter's clinical trials."

A Phase III clinical study assessed the safety and efficacy of TISSEEL in peripheral vascular surgery compared with manual compression, a standard of care, in 140 evaluable patients (70 patients per treatment arm). In the study, TISSEEL was shown to be statistically significantly better than manual compression in achieving hemostasis. These study results complement a clinical data package showing the safety and effectiveness of the use of TISSEEL as an adjunct to hemostasis.

"TISSEEL and its multiple application devices make it well-suited for a variety of surgical situations, such as open and laparoscopic procedures, reinforcing Baxter's commitment to supporting solutions to the surgical community," said Prof. Hartmut J. Ehrlich, M.D., vice president of global research and development in Baxter's BioScience business.

Source:

Baxter International Inc.,

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Baxter International Inc.. (2019, June 20). FDA approves Baxter's TISSEEL for general hemostasis in surgery. News-Medical. Retrieved on February 04, 2023 from https://www.news-medical.net/news/20120130/FDA-approves-Baxters-TISSEEL-for-general-hemostasis-in-surgery.aspx.

  • MLA

    Baxter International Inc.. "FDA approves Baxter's TISSEEL for general hemostasis in surgery". News-Medical. 04 February 2023. <https://www.news-medical.net/news/20120130/FDA-approves-Baxters-TISSEEL-for-general-hemostasis-in-surgery.aspx>.

  • Chicago

    Baxter International Inc.. "FDA approves Baxter's TISSEEL for general hemostasis in surgery". News-Medical. https://www.news-medical.net/news/20120130/FDA-approves-Baxters-TISSEEL-for-general-hemostasis-in-surgery.aspx. (accessed February 04, 2023).

  • Harvard

    Baxter International Inc.. 2019. FDA approves Baxter's TISSEEL for general hemostasis in surgery. News-Medical, viewed 04 February 2023, https://www.news-medical.net/news/20120130/FDA-approves-Baxters-TISSEEL-for-general-hemostasis-in-surgery.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
CTI completes recruitment in PERSIST-1 clinical trial of pacritinib for treatment of myelofibrosis